Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 10:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 63 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neoadjuvant Melanoma Clear all
Terminated Phase 1Phase 2 Interventional

A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

NCT04799054
View directory record Official record
Conditions
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Head and Neck Squamous Cell Carcinoma HNSCC, HPV-associated Cancers, Neoadjuvant Melanoma, Neoadjuvant Cutaneous Squamous Cell Carcinoma (cSCC)
Interventions
TransCon TLR7/8 Agonist, Pembrolizumab
Drug
Lead sponsor
Ascendis Pharma Oncology Division A/S
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Duarte, California • Los Angeles, California • Orange, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

NCT05081609
View directory record Official record
Conditions
Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
Interventions
TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
Drug · Procedure
Lead sponsor
Ascendis Pharma Oncology Division A/S
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
14
States / cities
Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

NCT04303169
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Vibostolimab, Gebasaxturev, MK-4830, Favezelimab + Pembrolizumab, ATRA
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 120 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
11
States / cities
Los Angeles, California • Santa Monica, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma

NCT03220009
View directory record Official record
Conditions
Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
Interventions
Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy
Procedure · Biological · Other + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2018 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

NCT00525031
View directory record Official record
Conditions
Melanoma
Interventions
Temozolomide (TMZ), Pegylated Interferon Alpha-2b (PGI)
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 15, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Tebentafusp for Uveal Melanoma

NCT06414590
View directory record Official record
Conditions
Locally Advanced Unresectable Uveal Melanoma
Interventions
Tebentafusp-Tebn
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Active, not recruiting Phase 3 Interventional

Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

NCT04949113
View directory record Official record
Conditions
Malignant Melanoma Stage III
Interventions
Neoadjuvant ipilimumab + nivolumab, Adjuvant nivolumab
Drug
Lead sponsor
The Netherlands Cancer Institute
Other
Eligibility
16 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma

NCT06365619
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 1 Interventional

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

NCT01608594
View directory record Official record
Conditions
Melanoma
Interventions
administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 15, 2026, 10:45 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED

NCT06548789
View directory record Official record
Conditions
Melanoma
Interventions
Prebiotic Xnack Packouts
Dietary Supplement
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Not yet recruiting Phase 2 Interventional

Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma

NCT07527325
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Fianlimab, Cemiplimab
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab

NCT04013854
View directory record Official record
Conditions
Melanoma Stage III, Melanoma
Interventions
nivolumab, Ipilimumab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Lancaster, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

NCT03972046
View directory record Official record
Conditions
Melanoma (Skin), Melanoma Stage IIIb-IVM1a, Metastasis Skin, Tumor Skin, BRAF Gene Mutation
Interventions
Talimogene laherparepvec (T-Vec), Dabrafenib (BRAF Inhibitor), Trametinib (MEK Inhibitor)
Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 15, 2026, 10:45 AM EDT
Active, not recruiting Phase 2 Interventional

Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma

NCT03757689
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Wide Excision and Sentinel Lymph Node (SLN) Biopsy
Drug · Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Louisville, Kentucky • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

NCT00588341
View directory record Official record
Conditions
Melanoma, Skin Cancer, Cancer
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 15, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants

NCT04495010
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
23
States / cities
Gilbert, Arizona • Tucson, Arizona • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Early Phase 1 Interventional

Immunogenicity and Biomarker Analysis of Neoadjuvant Ipilimumab for Melanoma

NCT00972933
View directory record Official record
Conditions
Melanoma
Interventions
ipilimumab
Drug
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 6, 2017 · Synced Sep 15, 2026, 10:45 AM EDT
Terminated Phase 2 Interventional Results available

Neoadjuvant Immunotherapy in Brain Metastases

NCT04434560
View directory record Official record
Conditions
Brain Metastases, Adult
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
Sarah Sammons, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Sep 15, 2026, 10:45 AM EDT
Recruiting Not applicable Interventional

The Multicentre Selective Lymphadenectomy Trial - 3

NCT07049276
View directory record Official record
Conditions
Cutaneous Melanoma, Stage III
Interventions
Index lymph node resection, Therapeutic lymph node dissection
Procedure
Lead sponsor
Melanoma Institute Australia
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Completed Phase 4 Interventional Results available

Neoadjuvant Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Cutaneous Stage L-lll Melanoma

NCT02451488
View directory record Official record
Conditions
Melanoma
Interventions
GM-CSF, Standard of Care
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 9, 2020 · Synced Sep 15, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

NCT04995094
View directory record Official record
Conditions
Pathologic Stage III Cutaneous Melanoma AJCC v8
Interventions
Imprime PGG, Pembrolizumab
Biological
Lead sponsor
HiberCell, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
4
States / cities
La Jolla, California • Whittier, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Sep 15, 2026, 10:45 AM EDT
Not yet recruiting Phase 2 Interventional

NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma

NCT07740941
View directory record Official record
Conditions
Melanoma (Skin Cancer), Melanoma Stage Stage IIIB, Melanoma Stage M1, Melanoma Stage IV
Interventions
Pembrolizumab, Ipilimumab plus nivolumab
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 15, 2026, 10:45 AM EDT
Withdrawn Phase 2 Interventional

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

NCT04007588
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
Nivolumab, BMS-986205, Ipilimumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 15, 2026, 10:45 AM EDT